ABL Bio Presents Preclinical Data of Leukemia Treatment at European Society for Medical Oncology Conference

[Asia Economy Reporter Chunhee Lee] ABL Bio announced on the 19th that it will attend the European Society for Medical Oncology Annual Meeting (ESMO Congress 2022) held in Paris, France from the 9th to the 13th of next month.

ESMO is one of the most prestigious societies playing a leading role in the field of oncology. The annual meeting, held every year, attracts oncology experts from around the world as well as industry stakeholders including global bio companies and multinational pharmaceutical firms, sharing various research achievements.

At this event, ABL Bio will give an oral presentation on the preclinical data of 'ABL602,' which is being developed as a treatment for acute myeloid leukemia (AML). The presentation will focus on the mechanism of action and anticancer effects of ABL602 confirmed in AML mouse models and leukemia progenitor cells from AML patients.

ABL602 is a bispecific antibody candidate that combines a CLL1 antibody targeting cancer cells and a CD3 antibody that activates immune T cells. ABL Bio designed ABL602 using a CD3 bispecific antibody structure targeting T cells so that it selectively eliminates leukemia stem cells expressing CLL1 without attacking normal hematopoietic stem cells.

Lee Sang-hoon, CEO of ABL Bio, said, “With growing global interest in CD3-based bispecific antibodies, attention to ABL602 is also increasing. Although still in the preclinical stage, ABL Bio’s bispecific antibody technology is showing strong potential not only in degenerative brain diseases and solid tumors but also in hematologic cancers, raising high expectations.”

This content was produced with the assistance of AI translation services.